A report from panel members appointed to the Eighth Joint National Committee titled "2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults" has garnered much attention due to its major change in recommendations for hypertension treatment for patients $60 years of age and for their treatment goal. In response, certain groups have opposed the decision to initiate pharmacologic treatment to lower blood pressure (BP) at systolic BP $150 mm Hg and treat to a goal systolic BP of <150 mm Hg in the general population age $60 years. This paper contains 3 sections-an introduction followed by the opinions of 2 writing groups-outlining objections to or support of maintaining this proposed strategy in certain at-risk populations, namely African Americans, women, and the elderly. Several authors argue for maintaining current targets, as opposed to adopting the new recommendations, to allow for optimal treatment for older women and African Americans, helping to close sex and race/ethnicity gaps in cardiovascular disease morbidity and mortality. (J Am Coll Cardiol 2014;64:394-402)
reports retained the same criteria, the SBP goal of <140 mm Hg for the general hypertensive cohort and <130/85 mm Hg for those with hypertension and either diabetes or CKD (1, 14) . In general, these recommendations have been maintained in the European and international guidelines to the present.
However, the failure of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial (15) , which compared very low SBP goals (<120 mm Hg) with the standard goal of <140 mm Hg, to demonstrate superiority of the lower goal has led the most recent European (4), AHA/ACC (3), and American Diabetes Association (16) guidelines to retreat from the recommendation of <140 mm Hg.
The JNC-8P process for developing its recommendations was based on rigid and carefully-applied criteria developed by the NHBLI for classifying the strength or weakness of available evidence. The 3 large randomized, placebo-controlled trials addressing hypertension in the elderly are summarized in Table 2 . Two of these trials recruited participants older than 60 years of age. The HYVET (Hypertension in the Very Elderly Trial) randomized 3,845 patients older than 80 years of age (17) The trial demonstrated significant reductions in incidence of LVH by electrocardiogram, need for cardiovascular surgery, and incidence of new atrial fibrillation (18) . Second, 2 Japanese trials comparing standard and lower goals, in a population not comparable with high-risk African Americans, failed to find benefit for the lower goals, but also found no harm or excessive adverse effects (19, 20 However, although only 1 of these trials will have all subjects >60 years of age, both trials compare goals near the standard (w140 mm Hg SBP) with lower goals.
If they clearly show benefit from a lower goal, then the goal of 150 mm Hg may be less defensible. But if, like in the ACCORD trial, they fail to demonstrate any benefit of a lower goal, the issue will not be resolved.
In the meantime, clinicians should be fully aware that all guidelines have an "escape clause," recognizing the need for good judgment in deciding whether to pursue a lower goal in healthy patients without adverse effects or accept that an office SBP of 140 to 150 mm Hg is acceptable for some. However, the pursuit of very low goals for those with hypertension and diabetes or coronary heart disease (CHD) is no longer supported by the available evidence. The J-curve for cardiovascular events has been suggested in retrospective analyses evaluating ontreatment BP and outcomes in clinical trials (21) .
Epidemiologic surveys support a J-curve for BP in diabetic groups (22) . There is concern about overly aggressive treatment of hypertension in older groups (23) . Overemphasis on a lower treatment goal for hypertension without taking the potential J-curve aspect into consideration might expose vulnerable groups (elderly women with hypertension, persons with diabetes, those with coronary disease, and frail older patients) to harm, so an optimal range for systolic pressure rather than a single threshold for treatment becomes more important (24) .
Members of JNC-8P, the ABC, and a Working Group on Women's Cardiovascular Health, as seen in the third section, are equally and intensely concerned about optimal prevention of cardiovascular disease through treating hypertension. Their debates will and should continue as we who treat hypertension in our daily practices seek to combine the best evidence and their recommendations with our judgment to improve the nation's health. 
